Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The PB2 protein is one of three subunits (alongside PB1 and PA) comprising the influenza A virus RNA polymerase complex. PB2 is responsible for binding the cap structure of host pre-mRNAs, a process called "cap-snatching" that enables the virus to prime transcription of its own mRNAs. PB2 also participates in the assembly and regulation of the polymerase complex, interacts with host factors, and modulates species adaptation and pathogenicity, in part via specific amino acid residues such as Lys627. The structure of PB2, especially the PB1-PB2 interface and cap-binding domain, is highly conserved and is the focus of antiviral drug development. PB2 additionally plays a role in evading host antiviral responses by suppressing interferon signaling pathways. Variations in PB2 are linked to differences in virulence, host range, and susceptibility to drugs.
Inhibition of cap-binding, blocking "cap-snatching" and viral mRNA synthesis; Disruption of polymerase complex assembly or PB1–PB2 interface; Inhibition of PB2–host protein interactions involved in immune evasion
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Polymerase basic protein 2 subunit of influenza A virus polymerase complex (PB2).